The invention generally relates to methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer. More specifically, the invention relates in part to the use of histone H3 lysine (27) trimethylation (H3K27me3), E-cadherin, and other biomarkers to treat cancer and determine the responsiveness of a cancer tumor to treatment with an immunotherapeutic agent.

The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells of a latent patient.

A method for assessing a cancer status of biological tissue includes the steps of: obtaining a Raman spectrum indicating a Raman spectroscopy response of the biological tissue, the Raman spectrum captured using a fiber-optic probe of a fiber-optic Raman spectroscopy system; inputting the Raman spectrum into a boosted tree classification algorithm of a computer program, and using the boosted tree classification algorithm for comparing, in real-time, the captured Raman spectrum to reference data and assessing the cancer status of the biological tissue based on said comparison, the reference data being previously determined based on a set of reference Raman spectra indicating Raman spectroscopy responses of reference biological tissues wherein each of the reference biological tissues is associated with a known cancer status; and generating a real-time output indicating the assessed cancer status of the biological tissue,

Provided herein are agents, such as antibodies, antibody-drug conjugates, or chimeric antigen receptors, that target B7-H3. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an B7-H3-targeting agent. The patient may be selected for treatment if the cancer expresses an increased level of B7-H3.

The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

The invention provides methods and compositions to detect expression of one or more biomarkers, including FGFR3, TP53, and/or EGFR, for treating, diagnosing, and providing a prognosis for cancer, e.g., bladder cancer. The invention also provides kits and articles of manufacture for use in the methods.

The present invention relates to methods of diagnosing and/or treating head and neck squamous cell carcinoma (HNSCC) in a subject. The present invention further relates to methods of diagnosing and/or treating head and neck squamous cell carcinoma (HNSCC) in a subject, wherein the subject has been diagnosed as being positive for human papillomavirus (HPV

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

Certain universal neoepitopes and cancer specific neoepitopes and methods therefor are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.

The present invention relates inter alia to methods of determining whether or not a subject suffering from oropharyngeal squamous cell carcinoma (OPSCC) is suitable for de-escalated treatment. The invention also provides methods of treating OPSCC, and associated assays and kits.